Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-05-13
2008-05-13
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S472000
Reexamination Certificate
active
10510610
ABSTRACT:
The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a benzazocine moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
REFERENCES:
patent: 4332810 (1982-06-01), Belanger et al.
patent: WO 02/24692 (2002-03-01), None
patent: WO 03 086314 (2003-10-01), None
patent: WO 03 086395 (2003-10-01), None
Khandwala et al. Endocrine Reviews, 2000, 21(3), 215-244.
“What is Cancer / General Definition of Cancer”. http://training.seer.cancer.gov/module—cancer—disease/units—whatiscancer1—definition.html, accessed Jul. 12, 2007.
Paradisi et al. Tetrahedron Asymmetry, 2000, 11 (22), 4617-4622.(based on HCAPlus abstract).
Amirkhosravi et al. Platelets, 1999, 10, 285-292.
Midgley et al. Expert Opinion in Investigational Drugs, 2001, 10(6), 1011-1019.
Paradisi et al. Tetrahedron: asymmetry, 2000, 11, 4617-22.
Belanger, et al., Can. J. Chem., vol. 61, pp. 2177-2182, 1993.
Iddon, et al., J. Chem. Soc. Perkin Trans., vol. 4, pp. 1083-1090, 1990.
Workman, et al., Seminars in Cancer Biology, vol. 3, pp. 369-381, 1992.
Belanger, et al., J. Org. Chem., vol. 47, pp. 4329-4334, 1982.
Paradisi, et al., Tetrahedron: Asymmetry, vol. 11, pp. 4617-4622, 2000.
Jarrell Noble
Merck & Co. , Inc.
Muthard David A.
Su Li
Wilson James O.
LandOfFree
Tyrosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tyrosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tyrosine kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3921221